Immuneering (NASDAQ:IMRX) Receives Buy Rating from Chardan Capital

Immuneering (NASDAQ:IMRX)‘s stock had its “buy” rating reiterated by equities research analysts at Chardan Capital in a report issued on Wednesday,Benzinga reports. They currently have a $13.00 price objective on the stock.

Other equities research analysts have also issued reports about the stock. Morgan Stanley lowered shares of Immuneering from an “equal weight” rating to an “underweight” rating in a report on Friday, December 13th. Needham & Company LLC restated a “buy” rating and issued a $15.00 price target on shares of Immuneering in a research note on Tuesday. One analyst has rated the stock with a sell rating, three have assigned a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $12.80.

Immuneering Price Performance

IMRX stock opened at $2.00 on Wednesday. Immuneering has a 1 year low of $1.00 and a 1 year high of $7.68. The firm has a market capitalization of $62.10 million, a P/E ratio of -1.02 and a beta of -0.34. The business’s 50-day moving average is $2.04 and its two-hundred day moving average is $1.77.

Institutional Investors Weigh In On Immuneering

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Vontobel Holding Ltd. acquired a new stake in shares of Immuneering during the third quarter worth about $25,000. Corsair Capital Management L.P. acquired a new stake in Immuneering during the 3rd quarter worth $25,000. Point72 Asia Singapore Pte. Ltd. purchased a new position in Immuneering during the 2nd quarter worth $44,000. XTX Topco Ltd increased its stake in Immuneering by 37.3% in the second quarter. XTX Topco Ltd now owns 34,159 shares of the company’s stock valued at $44,000 after purchasing an additional 9,274 shares during the period. Finally, Acadian Asset Management LLC acquired a new stake in shares of Immuneering during the second quarter worth about $67,000. 67.65% of the stock is owned by hedge funds and other institutional investors.

About Immuneering

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.